| Name | Title | Contact Details |
|---|
MTX Therapy Services is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SciMar is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Every day` 119`000 compassionate caregivers serve patients and communities through Providence St. Joseph Health` a national` Catholic` not-for-profit health system` driven by a belief that health is a human right. Rooted in the founding missions of the Sisters of Providence and the Sisters of St. Joseph of Orange` courageous women ahead of their time who brought health care and other social services to the American West when it was still a rugged` untamed frontier` we share a singular commitment to improve the health of all. From our earliest days` we’ve met new challenges by pioneering new solutions. Today` with 51 hospitals` 829 clinics and a comprehensive range of services` we strive to meet the needs of communities across Alaska` California` Montana` New Mexico` Oregon` Texas and Washington through a diverse family of Catholic` other faith-based and mission-driven secular organizations. Now` as we face a new frontier—a changing health care landscape—we draw upon their pioneering and compassionate spirit to plan for the next century of health for a better world` especially for the poor and vulnerable. If you need treatment` please visit www.providence.org to locate a health care provider.
Contexo Media is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.